Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

805 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases.
Cosimelli M, Golfieri R, Cagol PP, Carpanese L, Sciuto R, Maini CL, Mancini R, Sperduti I, Pizzi G, Diodoro MG, Perrone M, Giampalma E, Angelelli B, Fiore F, Lastoria S, Bacchetti S, Gasperini D, Geatti O, Izzo F; Italian Society of Locoregional Therapies in Oncology (SITILO). Cosimelli M, et al. Among authors: mancini r. Br J Cancer. 2010 Jul 27;103(3):324-31. doi: 10.1038/sj.bjc.6605770. Epub 2010 Jul 13. Br J Cancer. 2010. PMID: 20628388 Free PMC article. Clinical Trial.
Decrease of survivin, p53 and Bcl-2 expression in chemorefractory colorectal liver metastases may be predictive of radiosensivity radiosensivity after radioembolization with yttrium-90 resin microspheres.
Melucci E, Cosimelli M, Carpanese L, Pizzi G, Izzo F, Fiore F, Golfieri R, Giampalma E, Sperduti I, Ercolani C, Sciuto R, Mancini R, Garufi C, Diodoro MG, Mottolese M; Italian Society of Locoregional Therapies in Oncology (S.I.T.I.L.O.). Melucci E, et al. Among authors: mancini r. J Exp Clin Cancer Res. 2013 Mar 6;32(1):13. doi: 10.1186/1756-9966-32-13. J Exp Clin Cancer Res. 2013. PMID: 23497522 Free PMC article. Clinical Trial.
805 results